ClinicalTrials.gg
RecruitingNCT06058585CAPTIVATEUpdated Oct 5, 2026

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

A Phase 3 interventional study of Finerenone and Placebo Finerenone in Chronic Kidney Diseases, sponsored by The George Institute. Recruiting at 51 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by The George Institute · Phase 3, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 5, 2026Site recruiting status changedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.

Planned enrollment
2nd of 25
2,000 · median 100
Started
2024
with 4 others
Phase 3
6 of 25
3 open now
Primary completion
2029-12
later than 15 of 15 live
Registered
10th of 25
by date

Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2024, is one of 6 in phase 3, reaches primary completion later than 15 of the 15 other live ones, and was the 10th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing finerenone in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).

CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.

CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.

Read the detailed description

Chronic kidney disease (CKD) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. CKD progresses to kidney failure, increases the risk of early death, heart disease, and leads to a poorer quality of life.

Current treatments do not entirely remove the risk of kidney failure in people with CKD. To improve the outcomes of people with CKD, it is crucial to find the best treatment or combination of treatments that can slow CKD progression. CAPTIVATE aims to address this need.

CAPTIVATE has been designed to test multiple treatments within a common research platform. This design is more efficient and will lead to a shorter time for patients to receive effective treatments. The trial is 'eternal', which means that participants will continue to be recruited for many years until the trial is finally wound up. It is also 'adaptive', providing the flexibility to add new treatments, or remove those that are not working.

Participants can participate in more than one treatment at the same time or at different times. Participants receive each study treatment for 2 years. For each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. A final study visit occurs one month after the end of the 2-year treatment phase. Information collected at study visits include blood and urine test results, safety assessments and treatment adherence. Information about the overall health status of each participant is collected every 5 years.

03

Conditions studied

  • Chronic Kidney Diseases

Keywords

  • Chronic kidney disease
  • Mineralocorticoid Receptor Antagonist
  • Finerenone
  • Semaglutide
  • Glucagon-like peptide-1 receptor agonist
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Known chronic kidney disease from any cause ( ≥25 mL/min/1.73m2)
  3. Currently receiving standard of care treatment according to treating physician
  4. Eligible for randomisation in at least one recruiting domain-specific appendix
  5. Participant and treating physician are willing and able to perform trial procedures

Exclusion Criteria:

  1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
  2. less than 6 months

To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)

MRA domain

Inclusion Criteria:

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician.
  3. Treating physician believes finerenone is clinically appropriate for the participant.
  4. Participant and treating physician are willing and able to perform MRA DSA procedures.
  5. Provision of written or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures

Exclusion Criteria:

  1. Recipient of kidney transplant
  2. Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
  3. Current treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA.
  4. Known allergy, intolerance or to MRAs
  5. Current treatment with strong inhibitors
  6. Systolic BP \<110 mmHg or diastolic BP\<55 mmHg without antihypertensive therapy at time of screening
  7. Severe hepatic impairment (defined as Class C)
  8. Adrenal insufficiency
  9. Currently pregnant or breast feeding, or intending to become pregnant

GLP-1 RA Domain

Inclusion Criteria

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening.
  3. less than or equal to 10% (less than or equal to 86mmol/L)
  4. ≥23 kg/m2 and \< 50 kg/m2
  5. Treating physician believes semaglutide is clinically appropriate for the participant
  6. Participant and treating physician are willing and able to perform GLP-1 RA DSA procedures
  7. Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures

Exclusion Criteria

  1. Recipient of kidney transplant
  2. Major adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening
  3. Presently classified as being in (NYHA) Class IV heart failure
  4. Personal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)
  5. Previous episode of pancreatitis
  6. Uncontrolled thyroid disease TSH>6.0 mIU/L or \<0.4mlU/L
  7. Type 1 diabetes
  8. Current treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo).
  9. Known allergy, intolerance, or contraindication to GLP-1 RAs
  10. Currently pregnant or breast feeding, or intending to become pregnant or is of , and not using a highly effective method
  11. Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Finerenone

    Finerenone 10mg or 20mg tablets

    Drug: Finerenone

  • Placebo comparator
    Placebo Finerenone

    Finerenone matched placebo tablets

    Drug: Placebo Finerenone

  • Experimental
    Semaglutide

    Semaglutide 1.0 mg or 2.4 mg pen injector

    Drug: Semaglutide

  • Placebo comparator
    Placebo Semaglutide

    Semaglutide matched placebo pen injector

    Drug: Placebo semaglutide

Interventions

  • Finerenone 10mg or 20mg tablets, oral, once daily

    Also known as: BAY94-8862

  • DrugPlacebo Finerenone

    Finerenone matched placebo tablets, oral, once daily

  • Semaglutide 1.0mg or 2.4mg pen injector, subcutaneous injection, once weekly

  • DrugPlacebo semaglutide

    Semaglutide matched pen injector, subcutaneous injection, once weekly

06

What researchers measure

Primary outcomes

  1. Core Primary Outcome Measure

    The primary outcome is chronic eGFR slope. Chronic eGFR slope measures the rate of eGFR decline while on treatment. The duration of time over which chronic eGFR slope is computed can vary by domain and is determined by clinical considerations such as whether the investigational product can cause an acute decline in eGFR upon initiation. DSAs will specify the duration of time over which chronic eGFR slope is computed for the individual domain.

    Time frame: From randomisation to week 108

  2. MRA Domain Primary Outcome Measure

    Chronic eGFR slope estimated from all available eGFR values from week 4 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

    Time frame: From week 4 to week 108

  3. GLP1-RA Domain Primary Outcome Measure

    Chronic eGFR slope estimated from all available eGFR values from Week 0 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

    Time frame: From week 0 to week 108

Secondary outcomes

  1. Core Protocol Secondary outcomes

    1\. Change in albuminuria as measured by uACR (or uPCR if uACR unavailable) between week 0 and 24 weeks, measured as a continuous variable.

    Time frame: week 0 and 24 weeks

  2. Core Protocol Secondary outcomes

    2\. eGFR slope from week 0 to end of washout

    Time frame: week 0 to end of washout

  3. Core Protocol Secondary outcomes

    3\. Change in eGFR from week 0 to end of washout

    Time frame: week 0 to end of washout

  4. Core Protocol Secondary outcomes

    4\. Composite outcome of proportion of participants experiencing a ≥40% eGFR decline between week 0 and 108 weeks, and proportion of participants developing kidney failure (defined as eGFR \<15 mL/min/1.73m2 or chronic kidney replacement therapy start†) at 108 weeks.

    Time frame: between week 0 and 108 weeks

  5. Core Protocol Secondary outcomes

    5\. Time to a composite outcome of ≥40% eGFR decline from week 0 or kidney failure

    Time frame: from start of study drug (week 0) to washout (week 108) or kidney failure

  6. Core Protocol Secondary outcomes

    6\. All-cause mortality at 108 weeks

    Time frame: at 108 weeks

  7. Core Protocol Secondary outcomes

    7\. Proportion of participants experiencing one or more cardiovascular events (cardiovascular death, hospitalised heart failure, myocardial infarction, stroke)\* between week 0 and week 108

    Time frame: between week 0 and week 108

  8. Core Protocol Secondary outcomes

    8\. Time to first occurrence of a cardiovascular event

    Time frame: from start of study drug (week 0) to end of washout (week 108)

  9. Core Protocol Secondary outcomes

    9\. Safety and tolerability of treatment

    Time frame: from start of study drug (week 0) to end of treatment (up to week 104)

  10. Core Protocol Secondary outcomes

    10\. Change in quality of life measured using the Quality of Life Impact Survey for Kidney Disease (QDISCKD) at 6-monthly intervals from randomisation to week 108.

    Time frame: 6-monthly intervals from randomisation to week 108

  11. MRA Domain Secondary Outcome

    MRA DSA has a domain-specific secondary outcome that evaluates the time to the composite of ≥57% eGFR decline from week 0 or kidney failure

    Time frame: from start of study drug (week 0) to end of washout (week 108)

  12. GLP-1 RA Domain Secondary Outcome

    1\. Change in eGFR slope from Week 0 to Week 108.

    Time frame: from start of study drug (week 0) to end of washout (week 108)

  13. GLP-1 RA Domain Secondary Outcome

    2\. Time to composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to \<15 mL per minute per 1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from Week 0, or death from kidney-related or cardiovascular causes.

    Time frame: from start of study drug (week 0) to end of washout (week 108)

  14. GLP-1 RA Domain Secondary Outcome

    3\. Time to first occurrence of onset of persistent ≥50% reduction in eGFR from Week 0 to Week 108

    Time frame: from Week 0 to Week 108

  15. GLP-1 RA Domain Secondary Outcome

    4\. Time to first occurrence of a composite outcome of major adverse cardiovascular events (MACE) consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death

    Time frame: from start of study drug (week 0) to end of washout (week 108)

  16. GLP-1 RA Domain Secondary Outcome

    5\. Time to occurrence of all-cause death

    Time frame: from start of study drug (week 0) to end of washout (week 108)

  17. GLP-1 RA Domain Secondary Outcome

    6\. Change in body weight from Week 0 to Week 108

    Time frame: from Week 0 to Week 108

  18. GLP-1 RA Domain Secondary Outcome

    7\. Change in HbA1c from Week 0 to Week 108

    Time frame: Week 0 to Week 108

  19. GLP-1 RA Domain Secondary Outcome

    8\. Change in systolic blood/diastolic blood pressure from Week 0 to Week 108

    Time frame: from Week 0 to Week 108

  20. GLP-1 RA Domain Secondary Outcome

    9\. Change in NT-proBNP from Week 0 to Week 108

    Time frame: from Week 0 to Week 108

  21. GLP-1 RA Domain Secondary Outcome

    10\. Change in health status measured using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6-monthly intervals from randomisation to Week 108

    Time frame: from randomisation to Week 108

  22. GLP-1 RA Domain Secondary Outcome

    11\. Incidence of AEs and the following medical events of special interest (MESI) from Week 0 to end of trial: 1. Neoplasm (malignant and benign) 2. Pancreatitis, or persistent abdominal pain leading to a suspicion of pancreatitis 3. Acute gallstone disease (biliary colic or acute cholecystitis) 4. Thyroid disease 5. Cardiac arrhythmia (specifically, atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, torsade de pointes, second degree heart block type 2, third degree heart block, and symptomatic bradycardia requiring pacemaker placement) 6. Severe hypoglycaemic episodes 7. Immunogenicity events (allergic reactions, immune-complex disease, and lack of efficacy) 8. Adverse events leading to treatment discontinuation (if not any of the mentioned MESIs) 9. Ocular adverse events 10. Suspicion of transmission of infectious agents

    Time frame: Week 0 to end of trial

07

Study locations

49 of 51 sites recruiting
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
    Recruiting
    • Girish Talaulikar · Contact
  • Nepean Blue Mountains Local Health District
    Kingswood, New South Wales 2747, Australia
    Recruiting
    • Bhadran Bose · Contact
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
    Recruiting
    • Sunil Badve · Contact
  • John Hunter Hospital
    New Lambton Heights, New South Wales 2305, Australia
    Recruiting
    • Bobby Chacko · Contact
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Vincent Lee · Contact
  • Sunshine Coast Hospital and Health Service
    Birtinya, Queensland 4575, Australia
    Recruiting
    • Nicholas Gray · Contact
  • Townsville University Hospital
    Douglas, Queensland 4814, Australia
    Recruiting
    • Vikas Srivastava · Contact
  • West Moreton Hospital & Health Service
    Ipswich, Queensland 4305, Australia
    Recruiting
    • Sree Venuthurupalli · Contact
  • Gold Coast Hospital and Health Service
    Southport, Queensland 4215, Australia
    Recruiting
    • Jagadeesh Kurtkoti · Contact
  • Royal Adelaide
    Adelaide, South Australia 5000, Australia
    Recruiting
    • Michael Collins · Contact
  • Lyell McEwin Hospital
    Elizabeth Vale, South Australia 5112, Australia
    Recruiting
    • Nitesh Rao · Contact
  • Austin Health
    Heidelberg, Victoria 3084, Australia
    Recruiting
    • Sharon Ford · Contact
  • South Metropolitan Health Service, Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
    Recruiting
    • Suda Swaminathan · Contact
  • Gitam Institute of Medical Sciences and Research
    Visakhapatnam, Andhra Pradesh 530045, India
    Recruiting
    • Murty Mandapaka · Contact
  • Patna Medical College and Hospital
    Patna, Bihar 800001, India
    Recruiting
    • Harsh Vardhan · Contact
  • DKS Super Speciality Hospital, Raipur
    Raipur, Chhattisgarh 492002, India
    Recruiting
    • Varun Agrawal · Contact
  • Mysore Medical College
    Dehradun, Dehradun 248001, India
    Recruiting
    • Puneet Arora · Contact
  • GCS Medical College, Hospital & Research Centre
    Ahmedabad, Gujarat 380025, India
    Recruiting
    • Suvika Patel · Contact
  • Aman Hospital & Research Center Vadodara
    Vadodara, Gujarat 390007, India
    Recruiting
    • Aman Khanna · Contact
  • Father Muller Medical College Hospital
    Mangaluru, Karnataka 575002, India
    Recruiting
    • Manjunath Kulkarni · Contact
  • Dr Moopen's Medical College
    Meppādi, Kerala 673511, India
    Recruiting
    • Aneesh Basheer · Contact
  • CARE-CHL Hospital
    Indore, Madhya Pradesh, India
    Recruiting
    • Isha Tiiwari · Contact
  • Medway Hospital
    Chennai, Tamil Nadu 600024, India
    Recruiting
    • Shivakumar Dakshinamoorthy · Contact
  • Yashoda Hospital Hitec City
    Hyderabad, Telangana 500084, India
    Recruiting
    • Mahesh Kota · Contact
  • Apollo Hospitals
    Hyderabad, Telangana, India
    Recruiting
    • Haresh Patel · Contact
  • Charak Hospital and Research Centre
    Lucknow, Uttar Pradesh 226003, India
    Recruiting
    • Sakshi Jain · Contact
  • Shri Guru Ram Rai Medical College and Shri Mahant Indiresh Hospital
    Dehradun, Uttarakhand 248001, India
    Recruiting
    • Gaurav Shekhar Sharma · Contact
  • Fortis Hospital
    Kolkata, West Bengal 700107, India
    Recruiting
    • Upal Sengupta · Contact
  • North Bengal Medical College & Hospital
    Siliguri, West Bengal 734012, India
    Recruiting
    • Arpita Ray Chaudhury · Contact
  • Max Superspeciality Hospital, Dehradun
    Dehradun, 248001, India
    Not yet recruiting
    • Puneet Arora · Contact
  • Max Superspecialty Hospital, Ghaziabad
    Ghaziabad, 201012, India
    Recruiting
    • Manoj Kumar Singhal · Contact
  • Aarupadai Veedu Medical College & Hospital (AVMCH), Puducherry
    Puducherry, 607403, India
    Recruiting
    • Venkatesh A · Contact
  • Health New Zealand, Te Whatu Ora Te Matau a Maui, Hawke's Bay Hospital
    Hastings, Hawkes Bay 4120, New Zealand
    Recruiting
    • Hussain Allawati · Contact
  • Health New Zealand, Te Whatu Ora Waitemata, North Shore Hospital
    Auckland, 0620, New Zealand
    Recruiting
    • Ashik Hayat · Contact
  • Auckland City Hospital
    Auckland, 1023, New Zealand
    Recruiting
    • Dr Helen Pilmore · Contact
  • Aotearoa Clinical Trials Trust, Middlemore Hospital
    Auckland, 2025, New Zealand
    Recruiting
    • Kalpa Jayanatha · Contact
  • 201 Great King Street, Central Dunedin, Dunedin 9016, New Zealand
    Dunedin, 9016, New Zealand
    Recruiting
    • John Schollum · Contact
  • Midcentral - Palmerston North Hospital
    Palmerston North, 4442, New Zealand
    Recruiting
    • Dr Curtis Walker · Contact
  • Private Bag 9742 Maunu Road, Horahora, Whangārei 0148, New Zealand
    Whangarei, 0148, New Zealand
    Recruiting
    • Adam Mullan · Contact
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Vall d'Hebron University Hospital
    Horta-Guinardó, Barcelona 08035, Spain
    Recruiting
    • Dr Maria Jose Soler Romeo · Contact
  • Hospital Clinico Universitario València (INCLIVA)
    Valencia, Espana 46010, Spain
    Recruiting
    • Prof Jose Luis Gorriz Teruel · Contact
  • Jaffna Teaching Hospital
    Jaffna, Northern Province 4000, Sri Lanka
    Recruiting
    • Dr. Brammah Thangarajah · Contact
  • National Nephrology Specialized Hospital
    Colombo, Polonnaruwa 51000, Sri Lanka
    Recruiting
    • Dr Naseef Thaseem · Contact
  • University Hospital, Kotelawala Defence University
    Dehiwala, Western Province 10290, Sri Lanka
    Recruiting
    • Dr Dilukshi Pilapitiya · Contact
  • National Hospital of Sri Lanka
    Colombo, 00700, Sri Lanka
    Recruiting
    • Dr Mathu Selvarajah · Contact
  • Kandy National Hospital
    Kandy, 20000, Sri Lanka
    Recruiting
    • Dr Nishantha Nanayakkara · Contact
  • Kurunegala Teaching Hospital
    Kurunegala, Sri Lanka
    Recruiting
    • Dr Premil Rajakrishnan · Contact
  • Sri Jayewardenepura General Hospital
    Nugegoda, 10250, Sri Lanka
    Recruiting
    • Dr Harshani Perera · Contact
  • Peradeniya Teaching Hospital
    Peradeniya, 20400, Sri Lanka
    Recruiting
    • Dr Rajitha Abeysekera · Contact
  • Colombo North Teaching Hospital
    Ragama, 11010, Sri Lanka
    Recruiting
    • Dr Nalaka Herath · Contact
08

References and documents

Publications

  • Yeung EK, Rangaswami J, Tuttle KR, Grams ME, Tangri N, Vaduganathan M, Neuen BL. A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How? Clin J Am Soc Nephrol. 2026 Jun 23. doi: 10.2215/CJN.0000001158. Online ahead of print. PubMed 42335037 ↗
  • Shah NA, Du R, Neuen BL, Levin A, Jha V, Heerspink HJL, Kotwal SS; CAPTIVATE investigators. A Dose of Perspective: A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD. Kidney360. 2026 Aug 1;7(8):1772-1780. doi: 10.34067/KID.0000001227. Epub 2026 Jun 2. PubMed 42228487 ↗
  • Kotwal SS, Perkovic V, Jardine MJ, Kim D, Shah NA, Lin E, Coggan S, Billot L, Vart P, Wheeler DC, de Boer IH, Zhang H, Hou FF, Sugawara Y, Marion J, Lewis RJ, Berry LR, McGlothlin A, Jha V, De Nicola L, Gorriz JL, Heerspink HJL; GKPTN and CAPTIVATE Investigators. The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol. JAMA Netw Open. 2024 Dec 2;7(12):e2449998. doi: 10.1001/jamanetworkopen.2024.49998. PubMed 39661388 ↗
  • Heerspink HJL, Kretzler M. Clinical Trials for Kidney Disease in the Era of Personalized Medicine. J Am Soc Nephrol. 2024 Aug 1;35(8):1123-1126. doi: 10.1681/ASN.0000000000000412. Epub 2024 May 9. No abstract available. PubMed 39248631 ↗

Individual participant data

Plan to share: Yes — Trial data will be made available as a resource for future unspecified research, subject to any prior contractual obligations. Researchers wishing to gain access to the study resources will be required to submit an application for review by the Platform Oversight Committee, including a detailed project description, a list of data requested, and evidence of ethical approval. De-identified data extracts will be made available to approved proposals, and will not include data obtained from data linkage with local registries.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: TBC

Access criteria: Assessments of data requests will be based on sound science, benefit-risk balancing and research team expertise.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2029, 63 months after the start.

Of 41 non-industry phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 69. This study's planned 63 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Aug 2028 → Dec 2029 and completion Mar 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 28, 2023
StartActual
Sep 4, 2024
Primary completionEst.
Dec 31, 2029was Aug 2028
CompletionEst.
Dec 31, 2029was Mar 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added. Max Superspeciality Hospital, Dehradun is now Not yet recruiting
Show 8 added (3 India, 2 Spain, 2 Sri Lanka, 1 New Zealand)
  • Aman Hospital & Research Center Vadodara · Vadodara, India
  • Max Superspecialty Hospital, Ghaziabad · Ghaziabad, India
  • Aarupadai Veedu Medical College & Hospital (AVMCH), Puducherry · Puducherry, India
  • Midcentral - Palmerston North Hospital · Palmerston North, New Zealand
  • Hospital Germans Trias i Pujol · Badalona, Spain
  • Vall d'Hebron University Hospital · Horta-Guinardó, Spain
  • Jaffna Teaching Hospital · Jaffna, Sri Lanka
  • University Hospital, Kotelawala Defence University · Dehiwala, Sri Lanka
Oct 5, 2026
Primary completion
Aug 30, 2028→Dec 31, 2029
Oct 5, 2026
Study completion
Mar 31, 2029→Dec 31, 2029
Oct 5, 2026
Enrollment
1000→2000
Oct 5, 2026
Eligibility
Criteria largely rewritten (41 changes)
What changed in the criteria
  • AddedInclusion Criteria:
  • AddedExclusion Criteria:
  • AddedTo be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)
  • AddedMRA domain
  • AddedInclusion Criteria:
  • AddedUrine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  • AddedOn a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician.
  • AddedTreating physician believes finerenone is clinically appropriate for the participant.
  • AddedParticipant and treating physician are willing and able to perform MRA DSA procedures.
  • AddedProvision of written informed consent or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures
  • AddedExclusion Criteria:
  • AddedRecipient of kidney transplant
  • AddedHyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
  • AddedCurrent treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA.
  • AddedKnown allergy, intolerance or contraindication to MRAs
  • AddedCurrent treatment with strong CYP3A4 inhibitors
  • AddedSystolic BP <110 mmHg or diastolic BP<55 mmHg without antihypertensive therapy at time of screening
  • AddedSevere hepatic impairment (defined as Child-Pugh Class C)
  • AddedAdrenal insufficiency
  • AddedCurrently pregnant or breast feeding, or intending to become pregnant
  • AddedGLP-1 RA Domain
  • AddedInclusion Criteria
  • AddedUrine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  • AddedOn a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening.
  • AddedHbA1c less than or equal to 10% (less than or equal to 86mmol/L)
  • AddedBMI ≥23 kg/m2 and < 50 kg/m2
  • AddedTreating physician believes semaglutide is clinically appropriate for the participant
  • AddedParticipant and treating physician are willing and able to perform GLP-1 RA DSA procedures
  • AddedProvision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures
  • AddedExclusion Criteria
  • AddedRecipient of kidney transplant
  • AddedMajor adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening
  • AddedPresently classified as being in New York Heart Association (NYHA) Class IV heart failure
  • AddedPersonal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)
  • AddedPrevious episode of pancreatitis
  • AddedUncontrolled thyroid disease TSH>6.0 mIU/L or <0.4mlU/L
  • AddedType 1 diabetes
  • AddedCurrent treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo).
  • AddedKnown allergy, intolerance, or contraindication to GLP-1 RAs
  • AddedCurrently pregnant or breast feeding, or intending to become pregnant or is of child-bearing potential, and not using a highly effective contraceptive method

…and 1 more changes, on the record history on ClinicalTrials.gov ↗

Oct 5, 2026
Interventions
Added Drug: Semaglutide·Drug: Placebo semaglutide. Arms added: Semaglutide·Placebo Semaglutide
Oct 5, 2026
Primary outcomes
3 added, 1 removed
What changed in the outcomes
  • AddedCore Primary Outcome MeasureTime frame: From randomisation to week 108
  • AddedMRA Domain Primary Outcome MeasureTime frame: From week 4 to week 108
  • AddedGLP1-RA Domain Primary Outcome MeasureTime frame: From week 0 to week 108
  • RemovedeGFR slopeTime frame: From randomisation to week 108
Oct 5, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 42335037 ↗
Oct 5, 2026
Secondary outcomes
22 added, 6 removed
What changed in the outcomes
  • AddedCore Protocol Secondary outcomesTime frame: week 0 and 24 weeks
  • AddedCore Protocol Secondary outcomesTime frame: week 0 to end of washout
  • AddedCore Protocol Secondary outcomesTime frame: week 0 to end of washout
  • AddedCore Protocol Secondary outcomesTime frame: between week 0 and 108 weeks
  • AddedCore Protocol Secondary outcomesTime frame: from start of study drug (week 0) to washout (week 108) or kidney failure
  • AddedCore Protocol Secondary outcomesTime frame: at 108 weeks
  • AddedCore Protocol Secondary outcomesTime frame: between week 0 and week 108
  • AddedCore Protocol Secondary outcomesTime frame: from start of study drug (week 0) to end of washout (week 108)
  • AddedCore Protocol Secondary outcomesTime frame: from start of study drug (week 0) to end of treatment (up to week 104)
  • AddedCore Protocol Secondary outcomesTime frame: 6-monthly intervals from randomisation to week 108
  • AddedMRA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from Week 0 to Week 108
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from Week 0 to Week 108
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: Week 0 to Week 108
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from Week 0 to Week 108
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from Week 0 to Week 108
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from randomisation to Week 108
  • AddedGLP-1 RA Domain Secondary OutcomeTime frame: Week 0 to end of trial
  • RemovedChange in albuminuriaTime frame: From randomisation to week 24
  • RemovedComposite of 40% eGFR decline or kidney failureTime frame: From randomisation to week 108
  • RemovedAll-cause mortality at 108 weeksTime frame: 108 weeks
  • RemovedNumber of cardiovascular eventsTime frame: 108 weeks
  • RemovedSafety and tolerability of treatmentTime frame: 108 weeks
  • RemovedChange in quality of lifeTime frame: From randomisation to week 108
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 42335037 ↗
    8 sites added. Max Superspeciality Hospital, Dehradun is now Not yet recruiting
    Show 8 added (3 India, 2 Spain, 2 Sri Lanka, 1 New Zealand)
    • Aman Hospital & Research Center Vadodara · Vadodara, India
    • Max Superspecialty Hospital, Ghaziabad · Ghaziabad, India
    • Aarupadai Veedu Medical College & Hospital (AVMCH), Puducherry · Puducherry, India
    • Midcentral - Palmerston North Hospital · Palmerston North, New Zealand
    • Hospital Germans Trias i Pujol · Badalona, Spain
    • Vall d'Hebron University Hospital · Horta-Guinardó, Spain
    • Jaffna Teaching Hospital · Jaffna, Sri Lanka
    • University Hospital, Kotelawala Defence University · Dehiwala, Sri Lanka
    Primary completion Aug 30, 2028→Dec 31, 2029
    Study completion Mar 31, 2029→Dec 31, 2029
    Enrollment 1000→2000
    Eligibility Criteria largely rewritten (41 changes)
    What changed in the criteria
    • AddedInclusion Criteria:
    • AddedExclusion Criteria:
    • AddedTo be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)
    • AddedMRA domain
    • AddedInclusion Criteria:
    • AddedUrine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
    • AddedOn a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician.
    • AddedTreating physician believes finerenone is clinically appropriate for the participant.
    • AddedParticipant and treating physician are willing and able to perform MRA DSA procedures.
    • AddedProvision of written informed consent or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures
    • AddedExclusion Criteria:
    • AddedRecipient of kidney transplant
    • AddedHyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
    • AddedCurrent treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA.
    • AddedKnown allergy, intolerance or contraindication to MRAs
    • AddedCurrent treatment with strong CYP3A4 inhibitors
    • AddedSystolic BP <110 mmHg or diastolic BP<55 mmHg without antihypertensive therapy at time of screening
    • AddedSevere hepatic impairment (defined as Child-Pugh Class C)
    • AddedAdrenal insufficiency
    • AddedCurrently pregnant or breast feeding, or intending to become pregnant
    • AddedGLP-1 RA Domain
    • AddedInclusion Criteria
    • AddedUrine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
    • AddedOn a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening.
    • AddedHbA1c less than or equal to 10% (less than or equal to 86mmol/L)
    • AddedBMI ≥23 kg/m2 and < 50 kg/m2
    • AddedTreating physician believes semaglutide is clinically appropriate for the participant
    • AddedParticipant and treating physician are willing and able to perform GLP-1 RA DSA procedures
    • AddedProvision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures
    • AddedExclusion Criteria
    • AddedRecipient of kidney transplant
    • AddedMajor adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening
    • AddedPresently classified as being in New York Heart Association (NYHA) Class IV heart failure
    • AddedPersonal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)
    • AddedPrevious episode of pancreatitis
    • AddedUncontrolled thyroid disease TSH>6.0 mIU/L or <0.4mlU/L
    • AddedType 1 diabetes
    • AddedCurrent treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo).
    • AddedKnown allergy, intolerance, or contraindication to GLP-1 RAs
    • AddedCurrently pregnant or breast feeding, or intending to become pregnant or is of child-bearing potential, and not using a highly effective contraceptive method

    …and 1 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 3 added, 1 removed
    What changed in the outcomes
    • AddedCore Primary Outcome MeasureTime frame: From randomisation to week 108
    • AddedMRA Domain Primary Outcome MeasureTime frame: From week 4 to week 108
    • AddedGLP1-RA Domain Primary Outcome MeasureTime frame: From week 0 to week 108
    • RemovedeGFR slopeTime frame: From randomisation to week 108
    Secondary outcomes 22 added, 6 removed
    What changed in the outcomes
    • AddedCore Protocol Secondary outcomesTime frame: week 0 and 24 weeks
    • AddedCore Protocol Secondary outcomesTime frame: week 0 to end of washout
    • AddedCore Protocol Secondary outcomesTime frame: week 0 to end of washout
    • AddedCore Protocol Secondary outcomesTime frame: between week 0 and 108 weeks
    • AddedCore Protocol Secondary outcomesTime frame: from start of study drug (week 0) to washout (week 108) or kidney failure
    • AddedCore Protocol Secondary outcomesTime frame: at 108 weeks
    • AddedCore Protocol Secondary outcomesTime frame: between week 0 and week 108
    • AddedCore Protocol Secondary outcomesTime frame: from start of study drug (week 0) to end of washout (week 108)
    • AddedCore Protocol Secondary outcomesTime frame: from start of study drug (week 0) to end of treatment (up to week 104)
    • AddedCore Protocol Secondary outcomesTime frame: 6-monthly intervals from randomisation to week 108
    • AddedMRA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from Week 0 to Week 108
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from start of study drug (week 0) to end of washout (week 108)
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from Week 0 to Week 108
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: Week 0 to Week 108
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from Week 0 to Week 108
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from Week 0 to Week 108
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: from randomisation to Week 108
    • AddedGLP-1 RA Domain Secondary OutcomeTime frame: Week 0 to end of trial
    • RemovedChange in albuminuriaTime frame: From randomisation to week 24
    • RemovedComposite of 40% eGFR decline or kidney failureTime frame: From randomisation to week 108
    • RemovedAll-cause mortality at 108 weeksTime frame: 108 weeks
    • RemovedNumber of cardiovascular eventsTime frame: 108 weeks
    • RemovedSafety and tolerability of treatmentTime frame: 108 weeks
    • RemovedChange in quality of lifeTime frame: From randomisation to week 108
    Interventions Added Drug: Semaglutide·Drug: Placebo semaglutide. Arms added: Semaglutide·Placebo Semaglutide
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06058585
Lead sponsor
The George Institute
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Sep 4, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Enmoore Lin
Contact
captivate@georgeinstitute.org.au
61 2 8052 4511
Sradha Kotwal
study chair · The George Institute
Hiddo Lambers Heerspink
study chair · The George Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Finerenone · Semaglutide

Start the discussion